Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

Cash Flow Statement 
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Moderna Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (loss) 13 (1,279) (1,175) 217 (3,630) (1,380) 79 1,465 1,043 2,197 3,657 4,868 3,333 2,780 1,221 (272) (234) (117) (124) (123) (123) (135) (133)
Stock-based compensation 112 112 101 79 77 74 75 62 70 50 44 37 40 35 30 25 23 24 20 20 21 21 18
Depreciation and amortization 52 41 36 202 249 92 78 80 113 76 79 78 70 69 15 8 9 8 7 9 7 7 7
Leased assets expensed 62
Amortization/accretion of investments (21) (28) (27) (20) (12) (12) (17) (4) 6 11 18 21 20 8 5 5 3 1 1 (1) (1) (1)
(Gain) loss on equity investments, net 8 22 13 19 33 (35) 18
Deferred income taxes (106) 1,464 (220) (310) (86) (97) (230) (146) (229) (17) (22) (50)
Other non-cash items (1) 4 3 (18) 37 (8) (4) (8) 21 15
Accounts receivable, net (1,401) (26) 755 974 (1,634) 881 272 1,310 (4) 483 1 (33) (1,122) 1,190 (1,819) (1,200) (157) (26) (2) 3 (4) 2 6
Prepaid expenses and other assets (150) 3 202 914 70 (212) (1,030) (345) 90 (414) (303) (76) (98) (12) (173) (56) (7) (4) 8 (4) 3 3
Inventory (11) (104) (93) 285 228 18 216 1,128 (156) 21 (501) (476) (322) (148) (448) (47)
Right-of-use assets, operating leases (1) (78) 16 52 (648) (13) 4 (8) 9 10 10 (33) (11) (16) 2 3 (1) 2 (14) 2 (4) (5) 2
Accounts payable 96 104 (303) 21 179 (70) (117) 151 145 (21) (35) 178 (18) 59 (15) (2) 2 9 2 (5) (18) (3) 2
Accrued liabilities 49 (66) (398) (403) 696 (138) (495) 258 49 191 114 389 233 82 285 256 112 33 (13) 5 20 5 (33)
Deferred revenue (323) 179 (33) (887) (194) (160) (819) (1,466) (321) (1,565) (805) (1,607) 998 (233) 3,666 2,602 1,189 52 (11) (10) (7) (16)
Income taxes payable (2) (45) (11) 7 9 (19) 18 (18) (283) (1,243) 716 311 565
Operating lease liabilities 8 31 (6) (54) 593 8 4 13 (8) (9) (10) 9 10 (2) (3) (1) 15 (1) 10 5 (2)
Other liabilities 6 (141) 130 52 39 (3) (15) (185) 10 228 35 100 (417) 347 93 (1) 2 (1) 6 (6) (1) 1
Changes in assets and liabilities, net of acquisition of business (1,729) (146) 60 249 182 574 (1,144) 153 (904) (1,815) (889) (1,465) (170) 1,193 1,750 1,436 1,092 60 (10) (5) (11) (1) (37)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities (1,579) 5 186 405 2,030 465 (1,304) 197 (791) (1,893) (894) (1,558) (57) 1,283 1,750 1,537 1,126 93 18 24 16 26 (12)
Net cash provided by (used in) operating activities (1,566) (1,274) (989) 622 (1,600) (915) (1,225) 1,662 252 304 2,763 3,310 3,276 4,063 2,971 1,264 893 (24) (106) (99) (107) (109) (144)
Purchases of marketable securities (1,251) (846) (2,544) (1,663) (816) (196) (1,085) (2,510) (191) (3,162) (5,572) (2,373) (3,720) (5,833) (726) (630) (1,423) (282) (621) (196) (106) (414) (430)
Proceeds from maturities of marketable securities 1,112 1,963 1,573 864 1,447 1,904 1,360 929 813 968 441 263 215 521 339 389 231 247 270 245 184 160 404
Proceeds from sales of marketable securities 1,011 714 1,285 481 298 470 1,957 630 412 1,129 1,377 1,122 277 1,464 242 74 32 66 42 88 42 18 21
Purchases of property, plant and equipment (151) (182) (196) (220) (140) (234) (113) (92) (89) (87) (132) (120) (99) (30) (35) (23) (19) (19) (6) (7) (7) (11) (8)
Acquisition of business, net of cash acquired (85)
Investment in convertible notes and equity securities (23) (5) (35) (30)
Net cash (used in) provided by investing activities 721 1,649 118 (538) 789 1,944 2,011 (1,048) 945 (1,152) (3,921) (1,138) (3,327) (3,878) (180) (190) (1,178) 12 (316) 130 113 (247) (12)
Proceeds from public offerings of common stock, net of issuance costs 1,303 549
Proceeds from issuance of common stock through equity plans 8 32 15 15 6 16 9 25 11 17 12 28 32 36 28 50 30 78 28 31 16 4
Repurchase of common stock, including excise tax 1 (628) (526) (402) (1,006) (1,298) (623) (857)
Changes in financing lease liabilities 3 2 (1) (124) (65) (56) (25) (61) (46) (46) (31) (44) (34) (60) (2) (6)
Net cash provided by (used in) financing activities 11 34 14 (109) (58) (668) (542) (438) (1,041) (1,327) (642) (873) (2) (24) 26 44 30 1,381 578 31 16 4
Effect of changes in exchange rates on cash and cash equivalents 1
Net increase (decrease) in cash, cash equivalents and restricted cash (833) 409 (857) (25) (869) 361 244 176 156 (2,175) (1,800) 1,299 (53) 161 2,817 1,118 (256) 1,370 156 62 22 (351) (156)

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Moderna Inc. net cash provided by (used in) operating activities decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Moderna Inc. net cash (used in) provided by investing activities increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Moderna Inc. net cash provided by (used in) financing activities increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.